Opportunity Information: Apply for RFA CA 22 023
The Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) funding opportunity (RFA-CA-22-023) is a National Institutes of Health cooperative agreement announcement through the National Cancer Institute (NCI) under the Informatics Technology for Cancer Research (ITCR) Program. Its main goal is to support the advanced development and enhancement of emerging informatics technologies that can meaningfully improve how cancer-related data and knowledge are acquired, managed, analyzed, and shared across the full cancer research continuum. That continuum explicitly includes areas like cancer biology, diagnostics and treatment, early detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. The emphasis is on building technologies that can strengthen the end-to-end flow from data generation to usable knowledge, so that researchers and clinicians can work with cancer data more effectively and at larger scale.
A defining feature of this FOA is its focus on "emerging informatics technology" that is beyond the earliest stage of work. In practice, the technology should already be past initial prototyping and pilot development, with some proof that it works and evidence that it could have significant broader impact if improved. At the same time, it should not already be widely adopted in the cancer research field. That combination matters: the program is not aimed at brand-new concepts that still need basic feasibility testing, and it is also not aimed at mature, already-ubiquitous tools. Instead, it targets promising, partially validated technologies where additional engineering, functionality, usability, scalability, interoperability, or other enhancements could unlock much wider use and larger downstream benefits for cancer research and management.
Because this is a U24 cooperative agreement, the award structure implies substantial involvement and partnership with NIH/NCI staff compared to a typical research grant. Applicants are expected to propose a development plan that is clearly grounded in real-world cancer research needs and priorities, with a straightforward rationale for why the technology is needed, what gap it fills, and how the improved tool will benefit the broader cancer research community rather than only a single lab or institution. The FOA also makes user engagement a core expectation. Successful projects should build in concrete mechanisms to solicit, incorporate, and respond to feedback from target users and collaborators throughout development. That typically means planning for iterative development cycles, usability testing, pilot deployments with partner groups, documentation and training approaches, and dissemination strategies that support adoption by the larger community.
The scientific and technical scope is intentionally broad so long as it supports cancer research informatics. Projects can address technologies that improve data acquisition (for example, capturing clinical, imaging, pathology, genomic, or patient-reported data), data management (such as harmonization, curation, standards, metadata, governance, privacy-aware workflows), data analysis (including methods, platforms, pipelines, and reproducible computation), and data or knowledge dissemination (such as sharing, discovery, visualization, and integration of datasets and knowledge resources). The FOA explicitly allows clinical trials as optional, meaning a project may include a clinical trial component if it is appropriate to test or validate the informatics technology in a clinical or practice-related setting, but a clinical trial is not required.
Eligibility is broad and includes many organization types that commonly participate in NIH funding, spanning public and private institutions of higher education, nonprofits with or without 501(c)(3) status, for-profit organizations (other than small businesses), small businesses, and multiple levels of government (state, county, city/township, special districts), as well as independent school districts and public housing authorities/Indian housing authorities. It also includes federally recognized Native American tribal governments and tribal organizations that are not federally recognized tribal governments. The announcement also highlights additional eligible applicant categories such as Historically Black Colleges and Universities, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions, along with faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and non-U.S. (foreign) entities. This broad eligibility is consistent with a program that aims to advance community-facing informatics technologies and encourage participation from a wide range of institutions, including those serving populations affected by cancer inequities.
Administratively, the opportunity is listed as discretionary funding using the cooperative agreement funding instrument (U24) within the NIH health and education activity categories. The CFDA/assistance listings associated with the program include 93.393, 93.394, 93.395, 93.396, and 93.399. The opportunity record indicates an original closing date of 2022-11-17 and a creation date of 2022-03-24. While the excerpt does not provide an award ceiling or expected number of awards, the core takeaway is that the FOA is designed to invest in the next stage of high-potential cancer informatics tools: taking them from demonstrated early promise to a more robust, feature-complete, user-informed, and broadly adoptable technology that can accelerate cancer research and, ultimately, improve cancer-related outcomes.Apply for RFA CA 22 023
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.394, 93.395, 93.396, 93.399.
- This funding opportunity was created on 2022-03-24.
- Applicants must submit their applications by 2022-11-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) - RFA-CA-22-023
1) What is this funding opportunity?
This opportunity is the Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional), Funding Opportunity Announcement (FOA) RFA-CA-22-023. It is a National Institutes of Health (NIH) cooperative agreement administered through the National Cancer Institute (NCI) under the Informatics Technology for Cancer Research (ITCR) Program.
2) What is the main purpose of the FOA?
The main goal is to support advanced development and enhancement of emerging informatics technologies that can meaningfully improve how cancer-related data and knowledge are acquired, managed, analyzed, and shared across the cancer research continuum. The intent is to strengthen the end-to-end flow from data generation to usable knowledge so cancer researchers and clinicians can work more effectively and at larger scale.
3) What parts of the cancer research continuum are included?
The FOA explicitly includes cancer biology, diagnostics and treatment, early detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. The scope is meant to cover the full continuum as long as the focus is cancer research informatics.
4) What does "emerging informatics technology" mean in this FOA?
In this context, "emerging" means the technology is beyond the earliest stage: it should already be past initial prototyping and pilot development, with some proof it works and evidence it could have significant broader impact if improved. At the same time, it should not already be widely adopted across the cancer research field.
5) Is this FOA intended for brand-new ideas or prototypes?
No. The FOA is not aimed at brand-new concepts that still require basic feasibility testing. It targets technologies that have demonstrated early promise and partial validation, where additional development could enable broader use and larger downstream benefits.
6) Is this FOA intended for tools that are already widely used?
No. The FOA is not intended for mature, already-ubiquitous tools in the cancer research field. The focus is on promising tools that are not yet widely adopted and could become broadly useful with further enhancement.
7) What types of improvements is NCI looking to support?
The FOA emphasizes improvements that help unlock wider adoption and greater impact, including enhancements to engineering, functionality, usability, scalability, interoperability, and other features that make a technology more robust and community-ready.
8) What does it mean that this is a U24 cooperative agreement?
A U24 cooperative agreement implies substantial involvement and partnership with NIH/NCI staff compared to a typical research grant. Projects are expected to align with real-world cancer research needs and priorities, and to be developed with an eye toward community benefit and adoption.
9) What expectations are there for user engagement and feedback?
User engagement is a core expectation. Projects should include concrete mechanisms to solicit, incorporate, and respond to feedback from target users and collaborators throughout development. The FOA describes approaches such as iterative development cycles, usability testing, pilot deployments with partner groups, documentation and training, and dissemination strategies that support broader adoption.
10) Does the project need to benefit the broader community, or can it be tailored to one lab?
The FOA emphasizes community benefit. Applicants are expected to provide a rationale for the technology, the gap it fills, and how the improved tool will benefit the broader cancer research community rather than only a single lab or institution.
11) What scientific and technical areas can projects cover?
The scope is broad as long as it supports cancer research informatics. Projects may address technologies for data acquisition, data management, data analysis, and data or knowledge dissemination.
12) What are examples of "data acquisition" topics under this FOA?
Examples mentioned include capturing clinical, imaging, pathology, genomic, or patient-reported data, as long as the informatics technology advances cancer research and management.
13) What are examples of "data management" topics under this FOA?
Examples include harmonization, curation, standards, metadata, governance, and privacy-aware workflows. The emphasis is on improving how cancer data are organized and managed so they can be used more effectively.
14) What are examples of "data analysis" topics under this FOA?
Examples include methods, platforms, pipelines, and reproducible computation approaches that improve analysis of cancer-related data and support scalable, reliable research workflows.
15) What are examples of "data or knowledge dissemination" topics under this FOA?
Examples include sharing, discovery, visualization, and integration of datasets and knowledge resources, aimed at making cancer data and derived knowledge easier to find, combine, and use.
16) Are clinical trials allowed under this FOA?
Yes. The FOA is "Clinical Trial Optional," meaning a project may include a clinical trial component if appropriate to test or validate the informatics technology in a clinical or practice-related setting.
17) Are clinical trials required?
No. A clinical trial component is not required. It is optional and should only be included if it is appropriate for the technology being developed.
18) Who is eligible to apply?
Eligibility is broad. The FOA includes public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and multiple levels of government (state, county, city/township, special districts). It also includes independent school districts and public housing authorities/Indian housing authorities.
19) Are tribal governments and tribal organizations eligible?
Yes. The FOA includes federally recognized Native American tribal governments and tribal organizations that are not federally recognized tribal governments.
20) Are minority-serving institutions explicitly included?
Yes. The announcement highlights eligibility for institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions.
21) Are faith-based or community-based organizations eligible?
Yes. The eligibility description includes faith-based or community-based organizations.
22) Are U.S. territories or possessions eligible?
Yes. The announcement includes U.S. territories or possessions among eligible applicant categories.
23) Are non-U.S. (foreign) entities eligible?
Yes. The eligibility list includes non-U.S. (foreign) entities.
24) What is the funding instrument and how is it categorized?
The opportunity is listed as discretionary funding using the cooperative agreement funding instrument (U24) within NIH health and education activity categories.
25) What assistance listings (CFDA) are associated with this opportunity?
The associated CFDA/assistance listing numbers are 93.393, 93.394, 93.395, 93.396, and 93.399.
26) What are the key dates provided in the opportunity record?
The record indicates a creation date of 2022-03-24 and an original closing date of 2022-11-17.
27) Does the provided information include an award ceiling or number of awards?
No. The excerpt does not provide an award ceiling or the expected number of awards.
28) What is the core takeaway for applicants?
This FOA is designed to invest in the next stage of high-potential cancer informatics tools by taking technologies from demonstrated early promise to a more robust, feature-complete, user-informed, and broadly adoptable solution that can accelerate cancer research and improve cancer-related outcomes.
Browse more opportunities from the same category: Education, Health
Next opportunity: Bureau of Land Management New Mexico Environmental Quality and Protection
Previous opportunity: Bureau of Land Management Arizona Recreation and Visitor Services
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 22 023
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 22 023) also looked into and applied for these:
| Funding Opportunity |
|---|
| Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) Apply for RFA CA 22 024 Funding Number: RFA CA 22 024 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) Apply for RFA CA 22 022 Funding Number: RFA CA 22 022 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) Apply for RFA CA 22 021 Funding Number: RFA CA 22 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24 Clinical Trial Not Allowed) Apply for RFA CA 22 013 Funding Number: RFA CA 22 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Patient Derived Xenograft (PDX) Development and Trial Centers (PDTCs) Network (U54 Clinical Trial Not Allowed) Apply for RFA CA 22 012 Funding Number: RFA CA 22 012 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional) Apply for RFA DA 23 021 Funding Number: RFA DA 23 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed) Apply for RFA AI 22 025 Funding Number: RFA AI 22 025 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional) Apply for PAR 22 145 Funding Number: PAR 22 145 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Pediatric Immunotherapy Network (PIN) (U01 Clinical Trial Optional) Apply for RFA CA 22 016 Funding Number: RFA CA 22 016 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) Apply for RFA CA 22 020 Funding Number: RFA CA 22 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: $475,000 |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) Apply for RFA CA 22 025 Funding Number: RFA CA 22 025 Agency: National Institutes of Health Category: Education, Health Funding Amount: $2,000,000 |
| Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required) Apply for RFA DA 23 002 Funding Number: RFA DA 23 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) Apply for PAR 22 161 Funding Number: PAR 22 161 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Research Projects in Physical Sciences-Oncology (U01 Clinical Trial Optional) Apply for PAR 22 147 Funding Number: PAR 22 147 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) Apply for PAR 22 136 Funding Number: PAR 22 136 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional) Apply for PAR 22 131 Funding Number: PAR 22 131 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Interaction Targeted Epidemiology: Viral Suppression (LITE-VS) (UG3/UH3 Clinical Trial Optional) Apply for RFA AI 22 024 Funding Number: RFA AI 22 024 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) Apply for PAR 22 162 Funding Number: PAR 22 162 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11 Clinical Trials Not Allowed) Apply for PAR 22 153 Funding Number: PAR 22 153 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D71 Clinical Trial Not Allowed) Apply for PAR 22 152 Funding Number: PAR 22 152 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 22 023", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.